Evusheld™ Update: What Immunocompromised Patients Need to Know

The U.S. Food and Drug Administration (FDA) announced that Evusheld™ (a monoclonal antibody pre-exposure prophylaxis) is no longer authorized for use in the United States. As a result, UPMC no longer administers this medicine.

For information about the FDA announcement, read the article. Without an emergency use authorization (EUA), UPMC is no longer able to offer this medicine for the prevention of COVID-19.

The FDA paused its EUA of Evusheld because it is no longer effective against most COVID-19 variants currently circulating in our communities.

If you become sick, get tested for COVID-19. If your test is positive, talk with your provider as soon as possible to see if you are eligible for Paxlovid™, a pill, or remdesivir, an injection, to treat COVID-19 infections. If you have a weakened immune system, please remind your provider that you are at high risk to have a severe COVID-19 infection.

UPMC will work closely with the company that makes Evusheld and work hard to find new safe and effective prevention therapies.

You still should get the COVID-19 vaccine doses, including booster doses, that you are eligible to receive. Vaccines are one way to protect yourself from a serious COVID-19 infection.

Learn more about this update (PDF).